ToXchange Harnessing the T Cell for Cancer Immunotherapy: A Course on T Cell Redirection
SOT Virtual CE Course: PM12
Download the digital course book
Chair(s): Jessica Lynch, Janssen Research & Development; and Rafael Ponce, Shape Therapeutics.
Primary Endorser:
Immunotoxicology Specialty Section
Other Endorser(s):
Biotechnology Specialty Section; Regulatory and Safety Evaluation Specialty Section
Cancer immunotherapy is an area that has been of great interest in the last few years as several new therapeutic approaches have shown encouraging results in the clinic and subsequent approvals. The normal immune system has a protective capacity against tumor cells (immunosurveillance), while tumors can employ mechanisms that can result in an insufficient supply of activated and/or antigen-specific T cells within the microenvironment (tumor evasion). To overcome this immune-evasive mechanism, T cells can be redirected and expanded within the tumor microenvironment. CD3 redirection, which leverages protein-based therapeutics to simultaneously bind CD3 on T cells and a tumor associated antigen (TAA) on tumor cells, and engineered T cell–based therapeutics to redirect T cells to TAAs are emerging as powerful ways to harness the immune system to combat malignancies. The goal of this course is to provide the investigator with an overview of T cell redirection technologies and how to design a nonclinical safety strategy to understand safety liabilities. An overview of chimeric antigen receptor (CAR) T cells, T cell receptor (TCR) T cells, CD3 bispecifics, and immune mobilizing monoclonal TCRs against cancer (ImmTac) modalities will be provided. In addition, successful nonclinical safety strategies to support first-in-human clinical trials for these modalities will be shared. Overall, this course will provide a comprehensive overview of T cell redirection platforms, study design, and the challenges associated with these modalities.
-
Harnessing the T Cell for Cancer Immunotherapy: A Course on T Cell Redirection
An Introduction to Cancer Immunotherapy and the T Cell Redirection Course.—J.L. Lynch. Nonclinical Safety, Janssen Research & Development, Spring House, PA.
Generation of Synthetic Tumor Immunity through the Development of T Cell Redirecting Modalities.—R. Prell. Genentech Inc., South San Francisco, CA.
Engineered T Cells as Cancer Therapeutics: An Update on Their Design, Manufacture, and Clinical Experience.—R. Ponce. Shape Therapeutics, Seattle, WA.
Preclinical Safety Assessment of CAR and TCR T Cell Therapies.—T. Long. Juno Therapeutics, Seattle, WA. Sponsor: J. Lynch
Getting the Most out of Your Nonclinical Safety Studies for Antibody-Based CD3 Redirectors to Inform Deselection or Enable Firstin-Human Clinical Trials.—J. Shenton. Janssen Research & Development, Spring House, PA.
Regulatory Perspective on the Preclinical Development of T Cell Immunotherapies.—A. K. Galaro. US FDA/CBER, Silver Spring, MD. Sponsor: J. Lynch
Certificates
Course certificates are available to anyone who has registered for the course through SOT. If you would like to receive a certificate of completion, please contact us.
Feedback
Would you like to provide some feedback on our online courses? Complete the CE Course Online Survey and let us know what you think.